The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance

The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance

Source: World Health Organisation
Publication Date: June 17, 2013

View Guideline

2013 interim guidance from the World Health Organisation (WHO) on the use of bedaquiline in conjunction with other WHO-recommended treatments for multidrug-resistant (MDR) tuberculosis (TB). The objectives of this guidance document are: to evaluate the efficacy and safety of bedaquiline in addition to current WHO-recommended MDR TB treatments; to evaluate the balance between harms and benefits of the drug, its potential cost-effectiveness, patient and provider preferences and concerns, and the feasibility of introducing the drug into MDR TB programmes; and to provide, as appropriate, recommendations on the use of the drug as part of WHO-recommended MDR TB treatment regimens, including attention to concerns/constraints relevant to the potential use of a new drug for which phase III clinical trial data are not yet available.

Browse All Guidelines

Keywords: Tuberculosis - Resource-Limited Settings, Tuberculosis - Drug Resistance, Tuberculosis - First-line Therapy, Tuberculosis - Adverse Events, Tuberculosis - Treatment Complications, Tuberculosis - Drug-drug Interactions